Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 3/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPR3 | P17342 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224857 | 1.00 | MAPT (0.48) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL2870266 | 0.86 | CTSL (0.41) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL8141807 | 0.86 | CTSL (0.41) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL7343698 | 0.85 | NPSR1 (0.48) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL28516209 | 0.83 | NPSR1 (0.47) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL12627973 | 0.83 | NPSR1 (0.50) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL22311674 | 0.83 | NPSR1 (0.47) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL10210577 | 0.83 | NPSR1 (0.50) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL8708108 | 0.82 | KMT2A (0.39) | MAPTKMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL18256445 | 0.81 | MEN1 (0.35) | MAPTKMT2AMEN1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2015058868-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PANGAEA BIOTECH, S.L. (ES) | 2015-04-30 | — | — | WO | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1998054123-A1 | SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, UGT1A7 | MAPT 4063/4885KMT2A 2867/4885MEN1 1834/4885 |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | TPMT, UGT1A7, UGT2B7 | MAPT 3683/4885KMT2A 2633/4885MEN1 1337/4885 |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | MAPT 4708/4885KMT2A 4721/4885MEN1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.